Indeed, reduced levels of apolipoprotein A1 (ApoA-1) have been observed in the CSF of AD patients compared to MCI patients and healthy controls, suggesting its potential role as a fluid biomarker for AD diagnosis [66]. This evidence concerns the gene APOA1 and Alzheimer disease.